Sugi Predict

Sugi Predict / Compounds / SCHEMBL342736

SCHEMBL342736

SCHEMBL342736

Cc1ccccc1[C@@H](C)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 1/20 0.52
▸ GAA P10253 1/20 0.46
▸ TSHR P16473 3/20 0.45
▸ ACHE P22303 1/20 0.45
▸ ACP3 P15309 1/20 0.44
▸ GABRA1 P14867 2/20 0.42
▸ GABRB2 P47870 2/20 0.42
▸ SLC6A2 P23975 3/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ FAAH O00519 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ GABRB1 P18505 1/20 0.39
▸ GABRG2 P18507 1/20 0.39
▸ PTGS1 P23219 1/20 0.39
▸ HTR2C P28335 1/20 0.39
▸ GABRB3 P28472 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3073519 1.00 ESR1 (0.52) ESR1GAATSHRACHEACP3
SCHEMBL231827 1.00 ESR1 (0.52) ESR1GAATSHRACHEACP3
SCHEMBL13993318 0.86 ESR1 (0.59) ESR1GAATSHRACHEACP3
SCHEMBL30507724 0.83 ESR1 (0.56) ESR1GAATSHRACHEACP3
SCHEMBL5101317 0.83 GABRA1 (0.50) TSHRGABRA1GABRB2SLC6A2CYP3A4
SCHEMBL5101318 0.83 GABRA1 (0.50) TSHRGABRA1GABRB2SLC6A2CYP3A4
SCHEMBL382010 0.83 GABRA1 (0.50) TSHRGABRA1GABRB2SLC6A2CYP3A4
SCHEMBL14040083 0.82 ESR1 (0.50) ESR1GAATSHRACHEACP3
SCHEMBL17446315 0.82 ESR1 (0.50) ESR1GAATSHRACHEACP3
SCHEMBL6055139 0.82 ESR1 (0.50) ESR1GAATSHRACHEACP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688741-A1 COMPOUNDS FOR TREATING FIBROTIC DISEASES Meta-Immune, Inc. (KR) 2026-02-11 — — EP disclosed
US-12454530-B2 Amido cyclohexane acid derivatives as LPA receptor inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-10-28 — — US disclosed
US-12428430-B2 Oxabicyclo acids as LPA antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2025-09-30 — — US disclosed
WO-2024249867-A1 COMPOUNDS FOR TREATING FIBROTIC DISEASES AM SCIENCES (KR) 2024-12-05 — — WO disclosed
EP-4182301-B1 AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS CHIESI FARM SPA (IT) 2024-09-04 — — EP disclosed
WO-2023170025-A1 AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-09-14 — — WO disclosed
US-20230250093-A1 AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-08-10 — — US disclosed
US-20230212149-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-07-06 — — US disclosed
US-20230212149-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-07-06 — — US disclosed
EP-3853232-B1 OXABICYCLO ACIDS AS LPA ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-03-01 — — EP disclosed
US-20080227978-A1 Converting a carbonyl group within a substrate to a chiral alcohol moiety by reacting the carbonyl containing substrate with an organoaluminium reagent in the presence of a Group 5-12 transition metal based catalyst which is complexed with a chiral ligand; excellent yields THE UNIVERSITY OF NOTTINGHAM 2008-09-18 — — US disclosed
EP-1134226-B1 Process for producing an optically active ruthenium-phosphine complex and process for producing an optically active alcohol by using the complex TAKASAGO PERFUMERY CO LTD (JP) 2007-01-03 — — EP disclosed
US-20060142603-A1 Transition metal (rhodium or ruthenium) complex of a bis(diaryl- or dialicyclylphosphinoaryl) compound and an optionally substituted 1,2-diphenylethylenediamine; hydrogenation catalysts for forming an assymetric alcohol from an assymetric ketone; high optical purity and high yield TAKASAGO INTERNATIONAL CORPORATION (JP) 2006-06-29 — — US disclosed
EP-1661903-A1 NOVEL TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL WITH THE COMPLEX Takasago International Corporation (JP) 2006-05-31 — — EP disclosed
US-20040152736-A1 Thrombin receptor antagonists TOPROL ACQUISITION LLC 2004-08-05 — — US disclosed
US-6596887-B2 Reacting a ruthenium-phosphine complex with a specific optically active chiral diamine to deactivate one of the enantiomers and with another diamine to activate the other enantiomers TAKASAGO INTERNATIONAL CORPORATION (JP) 2003-07-22 — — US disclosed
EP-0901997-B1 Process for producing optically active alcohol compound TAKASAGO PERFUMERY CO LTD (JP) 2002-07-31 — — EP disclosed
US-20010039354-A1 Process for producing an optically active ruthenium-phosphine complex and process for producing an optically active alcohol by using the complex TAKASAGO INTERNATIONAL CORPORATION (JP) 2001-11-08 — — US disclosed
EP-1134226-A2 Process for producing an optically active ruthenium-phosphine complex and process for producing an optically active alcohol by using the complex Takasago International Corporation (JP) 2001-09-19 — — EP disclosed
EP-0901997-A1 Process for producing optically active alcohol compound Takasago International Corporation (JP) 1999-03-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12454530-B2 Amido cyclohexane acid derivatives as LPA receptor inhibitors LPAR1, LPAR2, LPAR3 ESR1 2034/4885GAA 1425/4885TSHR 1015/4885
US-20060142603-A1 Transition metal (rhodium or ruthenium) complex of a bis(diaryl- or dialicyclylphosphinoaryl) compound and an optionally substituted 1,2-diphenylethylenediamine; hydrogenation catalysts for forming an assymetric alcohol from an assymetric ketone; high optical purity and high yield ADH1A, ADH5, ADH1C ESR1 3292/4885GAA 3579/4885TSHR 3507/4885
US-20040152736-A1 Thrombin receptor antagonists CNR1, TBXA2R, CNR2 ESR1 732/4885GAA 3988/4885TSHR 97/4885
US-12428430-B2 Oxabicyclo acids as LPA antagonists LPAR1, LPAR2, LPAR3 ESR1 2577/4885GAA 2051/4885TSHR 980/4885
US-20230250093-A1 AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS LPAR1, LPAR2, LPAR3 ESR1 2034/4885GAA 1425/4885TSHR 1015/4885
US-20010039354-A1 Process for producing an optically active ruthenium-phosphine complex and process for producing an optically active alcohol by using the complex DRD4, PNMT, DRD1 ESR1 1927/4885GAA 4162/4885TSHR 983/4885
US-20230212149-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR3, LPAR1, LPAR2 ESR1 3054/4885GAA 1974/4885TSHR 196/4885
US-20080227978-A1 Converting a carbonyl group within a substrate to a chiral alcohol moiety by reacting the carbonyl containing substrate with an organoaluminium reagent in the presence of a Group 5-12 transition metal based catalyst which is complexed with a chiral ligand; excellent yields ADH5, ADH1C, CYP2E1 ESR1 2657/4885GAA 3672/4885TSHR 3877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.